Thistle and Reduced Alkaline Phosphatase Level

Across all 3 studies, beneficial effects of thistle (silymarin) on reducing alkaline phosphatase (ALP) levels were reported, with small to moderate effect sizes. 3 out of 3 studies found statistically significant reductions. The median study duration was 111 days across 2 studies that reported duration, indicating effects typically observed at around 16 weeks. The most studied population was clinical (e.g., breast cancer patients on chemotherapy, patients on antituberculosis drugs).

• Effective dose range: 140 mg daily
• Studied populations: female breast cancer patients undergoing chemotherapy, patients on antituberculosis drugs, healthy adults

Caveats: Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). One study used a multi-ingredient nutraceutical product, making it difficult to isolate the specific effect of thistle alone.